Roche, Isis Join 'Hunt' for Brain Cures in $392M Partnership
By Catherine Shaffer
Tuesday, April 9, 2013
Isis Pharmaceuticals Inc. and Roche AG have partnered to develop therapies for Huntington's disease using Isis antisense oligonucleotide (ASO) technology. The two companies will also work together to increase brain penetration of ASOs. Roche will pay $30 million up front to Isis, with milestone payments up to $362 million, including $80 million in commercial milestones.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.